The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2024 | Patient-reported outcomes from the DREAMM-8 trial of belantamab mafodotin in multiple myeloma
Meletios Dimopoulos, MD, National and Kapodistrian University of Athens School of Medicine, Athens, Greece, discusses the DREAMM-8 trial (NCT04484623), which showed that the combination of belantamab mafodotin plus pomalidomide and dexamethasone (PomDex) was superior to bortezomib plus PomDex in multiple myeloma. He highlights that, despite ocular toxicities associated with belantamab mafodotin, patient-reported outcomes were equal between the two treatment arms. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
